Results and prospects of development of new polyphenolic drugs for cancer patients

Vladimir N. Anisimov; Stig Larsen; Stig Lofberg; Irina A. Baldueva; Anastasia V. Malek; Tea Kirkegaard Nielsen; Elena I. Fedoros; Irina V. Perminova; Evgeny Yu. Drobyshev; Vladimir N. Bykov; Andrey V. Panchenko; Alexander M. Scherbakov; Alexey M. Belyaev

doi:10.18632/oncotarget.22307

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meeting Reports:

Results and prospects of development of new polyphenolic drugs for cancer patients

Vladimir N. Anisimov _, Stig Larsen, Stig Lofberg, Irina A. Baldueva, Anastasia V. Malek, Tea Kirkegaard Nielsen, Elena I. Fedoros, Irina V. Perminova, Evgeny Yu. Drobyshev, Vladimir N. Bykov, Andrey V. Panchenko, Alexander M. Scherbakov and Alexey M. Belyaev

PDF | HTML | How to cite

Oncotarget. 2017; 8:100951-100956. https://doi.org/10.18632/oncotarget.22307

Metrics: PDF 1128 views | HTML 1578 views | ?

Abstract

Vladimir N. Anisimov1, Stig Larsen2, Stig Lofberg3, Irina A. Baldueva1, Anastasia V. Malek1,4, Tea Kirkegaard Nielsen3,5, Elena I. Fedoros6,1, Irina V. Perminova7, Evgeny Yu. Drobyshev1,8, Vladimir N. Bykov9, Andrey V. Panchenko1, Alexander M. Scherbakov1 and Alexey M. Belyaev1

1 N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russia

2 Norwegian University of Life Sciences, Oslo, Norway

3 Meabco AS, Copenhagen, Denmark

4 Oncosystema LTD, Moscow, Russia

5 University of Copenhagen, Copenhagen, Denmark

6 Nobel LTD, Saint-Petersburg, Russia

7 M.V. Lomonosov Moscow State University, Moscow, Russia

8 Institute of Toxicology, Federal Medical-Biological Agency, Saint-Petersburg, Russia

9 S.M. Kirov Military Medical Academy, Saint-Petersburg, Russia

Correspondence to:

Vladimir N. Anisimov, email:

Keywords: cancer, breast cancer, clinical trial, polyphenols, cancer chemotherapy

Received: October 20, 2017 Accepted: October 25, 2017 Published: November 07, 2017

Abstract

The conference “Results and prospects of development of new polyphenolic drugs for cancer patients” took place at the N.N. Petrov National Medical Research Center of Oncology (PNMRCO) on May 31, 2017, and gathered researchers involved in development and evaluation of medicinal products based on the novel lignin-derived soluble polyphenolic polymer BP-Cx-1. BP-Cx-1 is the platform for a portfolio of innovative pharmacological products such as BP-C1, BP-C2 and BP-C3.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22307

Publication Alerts

Meeting Reports:

Results and prospects of development of new polyphenolic drugs for cancer patients

Abstract